AR070531A1 - Inhibidores de cinasa pim y metodos para su uso - Google Patents

Inhibidores de cinasa pim y metodos para su uso

Info

Publication number
AR070531A1
AR070531A1 ARP090100684A ARP090100684A AR070531A1 AR 070531 A1 AR070531 A1 AR 070531A1 AR P090100684 A ARP090100684 A AR P090100684A AR P090100684 A ARP090100684 A AR P090100684A AR 070531 A1 AR070531 A1 AR 070531A1
Authority
AR
Argentina
Prior art keywords
methyl
compounds
och3
pharmaceutically acceptable
pim kinase
Prior art date
Application number
ARP090100684A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055566&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR070531A1 publication Critical patent/AR070531A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente se refiere a compuestos de Ia formula (1), a sus tautomeros, estereoisomeros y polimorfos, y a las sales farmacéuticamente aceptables, ésteres, metabolitos o pro-fármacos de los mismos, a composiciones de los compuestos junto con vehículos farmacéuticamente aceptables, y al uso de los compuestos, ya sea solos o bien en combinacion con cuando menos un agente terapéutico adicional, en la inhibicion de la actividad de la cinasa Pim y/o en la profilaxis o el tratamiento de cáncer. Reivindicacion 1: Un compuesto de la formula (1), o un estereoisomero, tautomero, o una sal farmacéuticamente aceptable del mismo, en donde: R1 se selecciona a partir de los compuestos del grupo de formulas (2); X representa CH o N; R2a se selecciona a partir de amino, metilo, CH2F, CF3, C2H5, y H; R2b se selecciona a partir de H, y metilo; R3 se selecciona a partir de H, OH, OCH3, CH3, F, y CI; R4a se selecciona a partir de amino, metilo, OH, OCH3, OC2H5, F, CF3, H, y etilo; R4b se selecciona a partir de metilo, H, y F; R21 representa H o F; R22 representa H, CI, o F; R23 representa F, OC2H5, OCH3, CI, H, metilo, OH, u OCH(CH3)2; y R24 representa H u OH.
ARP090100684A 2008-03-03 2009-02-27 Inhibidores de cinasa pim y metodos para su uso AR070531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3335908P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
AR070531A1 true AR070531A1 (es) 2010-04-14

Family

ID=41055566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100684A AR070531A1 (es) 2008-03-03 2009-02-27 Inhibidores de cinasa pim y metodos para su uso

Country Status (21)

Country Link
EP (2) EP2262802B1 (es)
JP (1) JP5412448B2 (es)
KR (1) KR20100120709A (es)
CN (2) CN104098559A (es)
AR (1) AR070531A1 (es)
AU (1) AU2009221134B2 (es)
BR (1) BRPI0909102A2 (es)
CA (1) CA2717388A1 (es)
CL (1) CL2009000483A1 (es)
CO (1) CO6290687A2 (es)
EA (1) EA201001412A1 (es)
EC (1) ECSP10010447A (es)
ES (2) ES2562306T3 (es)
IL (1) IL207865A0 (es)
MA (1) MA32135B1 (es)
MX (1) MX2010009739A (es)
PE (1) PE20091577A1 (es)
TW (1) TW200942536A (es)
UY (1) UY31679A1 (es)
WO (1) WO2009109576A1 (es)
ZA (1) ZA201006128B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
RS58449B1 (sr) 2007-06-13 2019-04-30 Incyte Holdings Corp Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila
GEP20135849B (en) * 2008-09-02 2013-06-10 Novartis Ag Picolinamide derivatives as kinase inhibitors
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
SG10201405568UA (en) * 2009-09-08 2014-11-27 Hoffmann La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN102985417B (zh) 2010-03-10 2015-01-28 因塞特公司 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
PE20130405A1 (es) 2010-04-07 2013-04-10 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
EP2565192B9 (en) 2010-04-30 2015-11-25 The University of Tokyo Anticancer agent
EA035981B1 (ru) 2010-05-21 2020-09-09 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
WO2012120415A1 (en) * 2011-03-04 2012-09-13 Novartis Ag Tetrasubstituted cyclohexyl compounds as kinase inhibitors
CA2834166A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
CN102924446B (zh) * 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR088061A1 (es) 2011-09-27 2014-05-07 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013264831B2 (en) * 2012-05-21 2016-04-21 Novartis Ag Novel ring-substituted N-pyridinyl amides as kinase inhibitors
WO2014033631A1 (en) * 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014048939A1 (en) * 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN113384545A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
SI3489239T1 (sl) 2013-03-06 2022-04-29 Incyte Holdings Corporation Postopki in intermediati za pripravo zaviralca JAK
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
SG11201601259YA (en) * 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019057821A1 (en) * 2017-09-20 2019-03-28 Lead Discovery Center Gmbh COUMARIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND USES THEREOF IN THE TREATMENT OF CANCER
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
SI3746429T1 (sl) 2018-01-30 2023-01-31 Incyte Corporation Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
PE20050444A1 (es) * 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
WO2007000582A1 (en) * 2005-06-28 2007-01-04 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
CA2628455A1 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
CA2668255A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
WO2008054702A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
KR20090075869A (ko) * 2006-10-31 2009-07-09 쉐링 코포레이션 단백질 키나제 억제제로서의 2-아미노티아졸-4-카복실산 아미드
JP5330274B2 (ja) * 2007-03-01 2013-10-30 ノバルティス アーゲー Pimキナーゼ阻害剤およびその使用方法

Also Published As

Publication number Publication date
CN104098559A (zh) 2014-10-15
ECSP10010447A (es) 2010-10-30
PE20091577A1 (es) 2009-11-05
BRPI0909102A2 (pt) 2019-01-15
CA2717388A1 (en) 2009-09-11
EA201001412A1 (ru) 2011-06-30
CN102015701B (zh) 2014-07-23
EP2262802A1 (en) 2010-12-22
CL2009000483A1 (es) 2010-02-19
MX2010009739A (es) 2010-09-28
ES2562306T3 (es) 2016-03-03
EP2596790A1 (en) 2013-05-29
JP5412448B2 (ja) 2014-02-12
KR20100120709A (ko) 2010-11-16
UY31679A1 (es) 2009-09-30
CO6290687A2 (es) 2011-06-20
MA32135B1 (fr) 2011-03-01
ZA201006128B (en) 2011-10-26
ES2443496T3 (es) 2014-02-19
IL207865A0 (en) 2010-12-30
EP2262802B1 (en) 2013-10-23
TW200942536A (en) 2009-10-16
AU2009221134B2 (en) 2012-02-23
JP2011513363A (ja) 2011-04-28
WO2009109576A1 (en) 2009-09-11
AU2009221134A1 (en) 2009-09-11
CN102015701A (zh) 2011-04-13
EP2596790B1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
AR070531A1 (es) Inhibidores de cinasa pim y metodos para su uso
ES2526338T3 (es) Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
UY32490A (es) Inhibidores de beta-secretasa
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
SV2010003464A (es) Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas
AR064760A1 (es) Derivados de diazol como inhibidores de la eg-5
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
ECSP12011645A (es) Compuestos y métodos inhibidores de jak de pirazolopirimidina
EA200970856A1 (ru) Ингибиторы пути хеджхога
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
IL276711B1 (en) Arginase inhibitors and methods of using them
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
ES2587304T3 (es) Derivados de diaminopirimidina y procedimientos para la preparación de los mismos
NO20092226L (no) Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer
AR083017A1 (es) Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal